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Identification and classification of cancer types and subtypes is a major issue in current
cancer research. Whole genome expression profiling of cancer tissues is often the basis
for such subtype classifications of tumors and different signatures for individual cancer
types have been described. However, the search for best performing discriminatory gene-
expression signatures covering more than one cancer type remains a relevant topic in
cancer research as such a signature would help understanding the common changes in
signaling networks in these disease types. In this work, we explore the idea of a top down
approach for sample stratification based on a module-based network of cancer relevant
signaling pathways. For assembly of this network, we consider several of the most estab-
lished cancer pathways. We evaluate our sample stratification approach using expression
data of human breast and ovarian cancer signatures. We show that our approach performs
equally well to previously reported methods besides providing the advantage to classify dif-
ferent cancer types. Furthermore, it allows to identify common changes in network module
activity of those cancer samples.
Keywords: modeling of signaling pathway, cancer gene expression, expression signature, sample stratification,
microarray analysis
INTRODUCTION
Deregulation of growth regulating signaling pathways contributes
to an extensive alteration of cellular physiology and confers exces-
sive proliferation properties to cancer cells (Hanahan and Wein-
berg, 2000, 2011). Such perturbation of a cell’s signaling system
can for example be caused by mutations in upstream signaling pro-
teins (Gu et al., 2007), within coactivators of a signaling cascade
(Björklund et al., 2007), components of the downstream signal
transduction cascade (Irby et al., 1999; Bachman et al., 2004; Gar-
nett and Marais, 2004; Carpten et al., 2007), or loss of function
mutations of negative pathway regulators (Bonneau and Longy,
2000). Frequently, upregulated gene expression of growth factor
ligands and/or their receptors such as amplification and subse-
quent overexpression of ERBB2 (Yarden and Sliwkowski, 2001)
or Hedgehog (Ehtesham et al., 2007) can contribute to tumor
growth. Oncogenic pathway activation can then lead to secondary
transcriptional deregulation of factors that confer feedback within
the same pathway, such as the dual specific phosphatase (DUSP)
feedback inhibitors (Owens and Keyse, 2007). Furthermore, recent
work suggests that the mRNA expression pattern of signaling com-
ponents in cancer cells shows a certain plasticity in response to
drug treatment, a mechanism that might help cancer cells to evolve
into drug resistant cancer cell clones (Johannessen et al., 2010;
Nazarian et al., 2010). These and other studies are consistent with
the idea that mRNA expression levels of receptor coupled signal-
ing pathway components might directly reflect the activity status
of the respective pathway in a given tumor sample.
Tracking deregulation of signaling events in a given cancer sam-
ple is of great clinical interest as certain cancer types might be treat-
able with drugs developed to specifically inhibit receptor coupled
upstream signaling events thereby allowing personalized interven-
tion schemes. Thus, methods of cancer sample classification have
been developed that in principal are based on the mRNA expres-
sion status of a set of discriminatory signature genes. For example
(Bild et al., 2006) used the expression pattern of experimentally
derived pathway signature gene sets for successful stratification of
breast cancer patient samples. Other groups defined discrimina-
tory gene signatures for breast or ovarian cancer based on statistical
analysis of the expression profiles of a given set of cancer sub-
types (van’t Veer et al., 2002; Sorlie et al., 2003; Wang et al., 2005;
Denkert et al., 2009; Mok et al., 2009) or by defining a gene signa-
ture common to metastatic cancer samples (Rhodes et al., 2004).
In two exemplary studies, the mRNA expression data of multiple
patients was used as training sets to derive patient group intrinsic
differences of mRNA expression. These defined gene signatures
could then be used for successful stratification of independent test
groups of patients and may be used as clinically relevant indica-
tors of cancer status (van’t Veer et al., 2002; Sotiriou et al., 2006).
While those gene signatures provide indirect measures for pathway
activity in a sample set, more recent work has integrated gene-
expression profiles with molecular-pathway or protein–protein
interaction information (Peri et al., 2003; Chuang et al., 2007;
Chowdhury and Koyutürk, 2010; Dao et al., 2010; Eddy et al.,
2010). For example, Eddy and coworkers used 250 BioCarta path-
ways from MSigDB for improving their classification of cancer
samples. The method of Chowdhury and Koyutürk that relies on
matched tumor and control samples has been improved to suc-
cessfully predict the p53 status in breast cancer samples and liver
metastasis in colon cancer using networks of STRING derived
protein–protein interaction data. However, some of the studies
require an initial step to reduce the number of genes to be consid-
ered as differentially expressed which might be challenging for a
highly heterogeneous sample set. Also the studies do not address
potential inconsistencies in pathway annotations that might lead
www.frontiersin.org June 2013 | Volume 4 | Article 124 | 1
Research Topic: From structural to molecular systems biology: experimental and computational approaches to unravel mechanisms of kinase activity 
regulation in cancer and neurodegeneration
Kessler et al. Integrative analysis of cancer-related signaling pathways
to confusion about the relevance of the findings with regard to
well known cancer genes. For example, the BioCarta ERK pathway
consists of 28 genes including EGFR, IGF1R, and other receptor
tyrosine kinases (RTKs) while the well established cancer genes
ERBB2/3/4 are not included in the pathway. In turn, ERBB2–4
and EGFR are separately annotated components of the BioCarta
HER2-pathway, however, redundancies in the annotation arise
from annotation of RAF, MEK, and ERK as additional HER2-
pathway entities. Thus, a method that directly uses normalized
expression data as well as enhanced signaling network informa-
tion based on the functional relevance of a gene within a signaling
network might be considered as an alternative approach to sample
stratification.
To explore the possible value of such a top down network-based
classification approach we here compile a comprehensive list of
cancer-related signaling genes that we group into distinct signaling
core modules. To distinguish the core module genes with direct sig-
naling capacity from genes known for their rather indirect effect on
core modules, we define separate stimulating or inhibiting modi-
fier modules for those peripheral pathway components. Thereby,
we establish an interconnected network of cancer relevant signal-
ing modules mainly focusing on RTK-triggered pathways as well
as the HEDGEHOG, WNT, and NOTCH pathways. Subsequently
we identify expression values of individual network genes from
publicly available cancer sample expression data and compute the
median expression level of all module genes within a given sam-
ple as a representative measure for network module activity. For
this analysis we use published data sets of breast and ovarian can-
cer expression profiling studies as representatives of cancer types
with a high prevalence in the world population (Forouzanfar et al.,
2011).
Network module activity is then used for hierarchical and k-
means clustering to assess the networks usability for distinguishing
certain subtypes of cancer samples within the larger sample cohort.
We evaluate our network module-based clustering approach by
comparing it with established cancer specific discriminatory gene
signatures. Our results suggest that our alternative top down net-
work approach performs well when applied to cancers of different
origin.
RESULTS
COMPILATION OF COMPREHENSIVE MODULES OF CANCER-RELATED
SIGNALING PATHWAYS
For compilation of a network model of cancer-related signaling
pathways we identified signaling pathway components based on
information from the REACTOME pathway database (Matthews
et al., 2009; Croft et al., 2011) and screening of literature using
PUBMED guided by information provided by relevant review
articles (Hanahan and Weinberg, 2000, 2011; Shawver et al.,
2002; Perona, 2006; Lemmon and Schlessinger, 2010; Witsch
et al., 2010). We focused on a core network of well described
and frequently transcriptionally deregulated RTK-coupled sig-
naling pathways including EGFR/ERBB, FGFR, PDGFR, INSR,
and NGF as well as the serine/threonine kinase receptors of the
TGFB/BMP family (Ornitz et al., 1996; Nakagawara, 2001; Tal-
lquist and Kazlauskas, 2004; Krüttgen et al., 2006; Zhang et al.,
2006; Benyoucef et al., 2007; Massagué, 2008; Acevedo et al., 2009;
Belfiore et al., 2009; Turner and Grose, 2010; Wesche et al., 2011;
Pollak, 2012; Yarden and Pines, 2012). In addition, we consider
as relevant the non-kinase receptor coupled signaling pathways
NOTCH, HEDGEHOG, and WNT (Jarriault et al., 1995; Veeman
et al., 2003; Reya and Clevers, 2005; Klinakis et al., 2006; Palomero
et al., 2006; Sharma et al., 2006; Weng et al., 2006; Polakis, 2007;
Angers and Moon, 2009; Fortini, 2009; MacDonald et al., 2009;
Theunissen and de Sauvage, 2009; Ranganathan et al., 2011). RTK-
triggered signaling pathways use receptor specific adaptor protein
complexes to couple the activated ligand/receptor upstream com-
plexes to cytoplasmic downstream signaling cascades including
RAS/MEK/ERK, JNK, p38, and PI3K/AKT signaling (Lowenstein
et al., 1992; Buday et al., 1994; Birge et al., 1996; Okada and Pessin,
1996; Li et al., 2001; Ravichandran, 2001; Malumbres and Bar-
bacid, 2003; Gotoh, 2008; Ursini-Siegel and Muller, 2008) as well
as to CDC42/RAP1/RAC1, small GTPases which regulate actin
dependent cell movements and also activation of JNK signaling
(Feller, 2001; Eden et al., 2002; Miyamoto et al., 2004). In addi-
tion to recruitment of adaptor proteins, activated RTKs present a
binding and activating interface for several other cancer relevant
signaling cascades including PLCG, SRC, and STAT (Noh et al.,
1995; Kamat and Carpenter, 1997; Ishizawar and Parsons, 2004;
Yu et al., 2009). Our network contains distinct modules covering
these RTK-specific adaptor and signaling proteins as well as the
downstream cascades that transduce the growth factor signal to
the level of transcriptional regulation. In the case of HEDGEHOG
and WNT signaling, ligands are bound by seven-transmembrane-
domain proteins (Smoothened or Frizzled class) with help of
co-receptors. Signaling events are then initiated via recruitment
of cytoplasmic factors. In case of NOTCH signaling, the initia-
tion of downstream signaling events includes a series of tightly
regulated cleavage events that, upon ligand binding, lead to the
proteolytic release of the transcriptionally active cytoplasmic tail
of NOTCH (NICD).
The principal structure of our network assumes that function-
ally similar core genes can be grouped into the same module within
the network, exemplified by a LIGAND-, a RTK/RECEPTOR-, and
an ADAPTOR module (Figure 1B). Factors that are themselves
not bona fide ligands, RTKs, or adaptor proteins but are known
to modify activity of a pathways upstream modules are grouped
into separate CoActivator and CoInhibitor modules, respectively.
In the network upstream modules connect to downstream mod-
ules containing the genes encoding for proteins that transduce the
signal toward transcription factors and subsequent gene regulatory
events. These core downstream modules are complemented by
separate modules covering genes encoding for factors with indirect
modulating effects on the level of signal transduction cascades. We
believe that separating indirectly activating and inhibiting factors
from pathway core modules allows assessment of the functional
importance of a module throughout different levels of the network
hierarchy more directly than in previously published pathway
databases (KEGG/REACTOME) that tend to assign core compo-
nents as well as components with more general modifying function
to the same pathway. The nine major cancer-related signaling path-
ways that we assembled into a module-based network consist of
719 edges and 592 nodes covering 558 genes (Figure 1A; Table S1
in Supplementary Material).
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FIGURE 1 | Interconnected signaling network of cancer-related genes
and modules. (A) Representation of the cancer relevant signaling network
including all modules and contributing genes. (B) Exemplified schematic
layout of the module grouping strategy; all genes in the network were
associated with functional modules, e.g., genes encoding ligands, RTKs, or
adaptor proteins of a given pathway were grouped into the corresponding
ligand, RTK, or adaptor modules. In living cells, these modules contribute to
activity of the pathways upstream signaling, here represented by a pathway
upstream module. Functionally, the pathway upstream module of a given
pathway activates or inhibits the activity of distinct downstream modules,
here exemplified for activation of a MAPK and a PI3K/AKT module. These
modules themselves consist of associated genes, e.g., encoding for ERK,
RAS, or RAF isoforms in case of MAPK signaling or PI3K catalytic and
regulatory isoforms as well as AKT, PTEN, and others. In our network, these
downstream modules are again linked to events acting further downstream
in the pathway, like activation of an AP1 or MYC transcription factor module.
APPLICATION OF THE SIGNALING NETWORK FOR ANALYSIS OF
PATHWAY ACTIVITY IN CANCER SAMPLES
Signaling activity in breast and ovarian cancer has been reported
to be perturbed on the level of expression of several genes that
correspond to upstream signaling modules represented in our
network (Bell et al., 2011; Koboldt et al., 2012). We therefore
reasoned that module-based network activity could be applied
to distinguish subsets of cancer samples of these two origins. To
address this point, we first mapped the overlap of all genes in our
signaling network with two independent publicly available breast
cancer or ovarian cancer gene-expression data sets, respectively.
We then determined the network module activity for each of the
samples by calculating for all modules the median expression value
of all genes attributed to the same module (Anglesio et al., 2008;
Lu et al., 2008; Tothill et al., 2008). We chose these particular data
sets for our analysis as the sample sizes are relatively large, allow-
ing to compute meaningful p-values in the statistical analysis of
a k-means clustering approach. Also, most samples from these
studies are annotated well with respect to multiple clinical mark-
ers in each of the studies, an annotation depth rarely seen in other
publicly available data sets. Therefore, we reasoned that these data
sets allow us to simultaneously test for the association of network
module activity with several phenotypic markers at once.
Complete linkage hierarchical clustering using network mod-
ule activity is consistent with two main clusters of breast cancer
samples from the Lu et al. (2008) data set (Figures 2A,B). The
ductal samples in the left cluster appear to be differentiated from
all other samples mainly by their estrogen receptor (ER) and HER2
expression statuses and high tumor grade (Figure 2B). In compar-
ison, clustering the expression values of all network genes results
in an apparently less stringent sample discrimination regarding
some of the clinical sample properties, e.g., high grade ER-negative
samples co-cluster with comparably more ER-positive samples
(Figure 2C). To qualitatively compare our network-based clus-
tering with established breast cancer specific discriminative gene
signatures, we performed hierarchical bi-clustering using those
gene-expression values that were covered by the breast cancer pri-
mary data. We used three breast cancer specific gene signatures
(van’t Veer et al., 2002; Paik et al., 2004; Wang et al., 2005) and a sig-
nature developed for discrimination of tumor grades of multiple
different solid tumors (Rhodes et al., 2004). Clustering the breast
cancer samples according to the van’t Veer et al. (2002) and Wang
et al. (2005) gene-expression signature resulted in separation of
two main clusters of similar size, where one cluster is dominated by
high grade ER-negative, HER2-negative samples (Figures 2D,E).
Essentially similar results are obtained using the Paik et al. (2004)
and Rhodes et al. (2004) gene signatures (Figures 2F,G).
We noted that activity of several modules associated with the
same signaling branch appear to contribute most to separation
of the high grade ER-negative and HER2-negative cluster from
all other samples of the data set (Figures 3A,B). Generally, the
distribution curve of network module activity values is overall sim-
ilar to the expression values of the genes that are associated with
these modules; as one would expect from calculated median gene-
expression values the network module activity value distribution is
slightly more confined with regard to maximal and minimal values
and shows a reduced amplitude (Figure 3C). We concluded that
the overall network module activity reflects the general expression
dynamics within the network. We next sought to identify modules
and candidate genes attributed to those pathway modules that
show differential activation and expression levels between sample
subsets. To visualize the differences in average gene expression and
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FIGURE 2 | Hierarchical clustering of a breast cancer sample set. (A)
Heatmap representation of a complete linkage hierarchical bi-clustering of
network module activity, based on expression data of 113 breast cancer
samples of Lu et al. (2008) data set; the resulting dendrogram is annotated
according to the clinical sample annotation using the color code as
indicated in the legend; labelings are from top to down: labeling 4, tumor
type; labeling 3, tumor grade; labeling 2, HER2 expression status; labeling
1, estrogen receptor (ER) expression status; regions analyzed in more
detail in Figures 3A,B are indicated by black vertical bars. (B)
Magnification of the dendrogram from (A) showing the cluster of mainly
ER-negative, mainly HER2-negative, high grade ductal samples that is
separated from all other samples. (C) Cluster dendrogram resulting from
bi-clustering based on expression values of all individual genes
represented in the network. (D–G) Cluster dendrograms resulting from
bi-clustering of the breast cancer samples based on expression values of
published discriminative gene signature sets generated specifically for
breast cancer samples (D) Wang et al. (2005) (E) van’t Veer et al. (2002) a
signature generated more generally to distinguish cancer samples from
each other (F) Rhodes et al. (2004) and another breast cancer specific
signature from Paik et al. (2004) (G).
network module activity between the high grade ER- and HER2-
negative cluster and all other samples we mapped the differences to
a subset of the signaling network containing the most deregulated
modules (top 15% of differential module activity/gene expres-
sion; Figure 3D). Apparently, the modules/genes showing the
largest difference between the clusters are related to the INSR and
PDGFR pathways as well as the MAPK, NFkB, and AP1 branches.
For example, the lower PDGFR-RTK module activity in the high
grade cluster comparing to all other samples appears to result from
differential expression of both PDGFRA and PDGFRB while the
lower PDGFR-CoActivator module activity appears to result from
expression differences of the PLAT/tissue Plasminogen Activator
(tPA), which is, among other functions, a proteolytic activator
of PDGFC (Fredriksson et al., 2004). INSR-RTK and INSR-Ligand
module activity differences appear to arise primarily from reduced
expression of IGF1R, IGF2R, and IGF2. These findings suggest,
that PDGFR- and INSR-pathway sub-network activity in the high
grade breast cancer samples of the Lu et al. (2008) data set might
be relatively low compared to all other samples due to signal-
ing modulation on the level of growth factor reception as well
as on the level of the enzyme that mediates the posttranslational
activation of the signaling pathway. In contrast, network mod-
ule activity of the TGF/BMP-Adaptor, the Downstream-MAPK,
AP1, the NFkB-SignalingComplex, and the NFkB-Inhibitor mod-
ules might be dominated in the high grade cluster relative to all
other samples due to the expression differences of SHC1, MEK1,
FOS-isoforms, NFkBIA/E/Z, IRAK1, and MYD88, respectively.
We next asked if similar pathway activity in high grade
ER-, HER2-negative breast cancer samples could be identified
in an independent data set. To address this point, we per-
formed an analogous analysis of breast cancer samples pro-
vided by the Expression Project for Oncology data set (expO;
expo.intgen.org/geo/home.do). Clustering the network module
activity of these samples results in separation of one main-
cluster containing a mixed population of high and low grade,
ER-negative or positive but predominantly HER2-negative sam-
ples from all other samples constituting the heterogeneous second
main cluster on the right hand side (Figure 4A). This second
main-cluster comprises a large subcluster of mainly high grade
ER- and HER2-negative samples and we chose this subcluster for
further analysis of differential module activity comparing to all
other samples. Modules contributing to sample clustering were
identified (Figure 4B) and generally the distribution of network
module activity again reflects the distribution of gene-expression
associated with the network (Figure 4C). We then mapped the dif-
ferentially activated modules/genes to the relevant sub-network
as described above and we find that the network of differential
module and gene activity from this second set of breast can-
cer samples partially overlaps with the sub-network identified
as relevant for the Lu et al. (2008) data set. In particular, mod-
ules related to the PDGFR and INSR related subnetworks score
among the top 15% of differentially activated modules and both
pathways thereby show highly similar differential activity between
high grade and all other samples in both data sets (Figure 4D).
Comparing module activity values for both data sets shows that
PDGFR-CoActivator and PDGFR-RTK modules can be identi-
fied as differentially activated above threshold in both data sets
while PDGFR-Adaptor, PDGFR-Ligand PDGFR-CoInhibitor, and
PDGFR-Downstream-JAK/STAT modules do not show differential
activation in both data sets (Figure 4E). Similarly, the INSR-Ligand
and INSR-RTK modules show differential activation above thresh-
old in both data sets while INSR-CoInhibitor and INSR-Adaptor
modules are not identified as differentially activated (Figure 4F).
We conclude that a subset of PDGFR and INSR-pathway mod-
ules scores among the top 15% differentially activated modules
as judged by thresholds generated for each of the data sets indi-
vidually suggesting that those modules are differentially activated
between high grade and all other samples in a way that is com-
parable between the data sets. When we compared differential
expression of those genes that appear to contribute to the dif-
ferential network module activity we found that for the PDGFR
signaling branch the differential expression between high grade
and all other samples of PDGFRA, PDGFRB, and PLAT exceeds the
threshold in both data sets (Figure 4G). For the INSR branch we
find that the IGF2 ligand as well as the IGF1R RTK and IGF2R show
similar differences between the high grade cluster and all other
samples in both data sets while the IGF1 ligand appears to be dif-
ferentially expressed in the expO data set only (Figure 4H). Taken
together, our analysis suggests that our network-based approach
might be feasible for hierarchical clustering to identify interesting
sub-populations in breast cancer data sets and for a first visual
inspection of expression differences in these data sets preceding
a more detailed analysis and verification of the underlying gene
regulatory changes.
ANALYSIS OF PATHWAY ACTIVITY OF OVARIAN CANCER SAMPLES
In the next step of our analysis we wanted to test whether our
network-based stratification approach might also be applicable to
another cancer type and we therefore performed hierarchical clus-
tering of ovarian cancer samples of a large patient cohort that is
well annotated with regard to clinical parameters as provided by
Tothill et al. (2008). Hierarchical clustering of network module
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FIGURE 3 | Pathway activity analysis of a high grade breast cancer
subcluster. (A,B) Regions of the heatmap in Figure 2A that appear to
distinguish high grade ER-negative HER2-negative samples from all other
samples in the Lu et al. (2008) data set. (C) Plot showing distribution of
log10 values of all network module activity values (blue bars) for all breast
cancer samples versus log10 gene-expression values (green bars) of all
genes associated with the network. (D) Network diagram of the top 15%
differentially expressed modules comparing the difference between
average network module activity in high grade versus all other samples;
node color and node label size are initialized with log2 difference of the
average module and gene-expression values of high grade versus all other
samples, respectively; a dark red color indicates log2 difference ≥5.04 as a
cutoff for the largest 15% fraction of differentially expressed network
modules or genes (max. 9.28).
activity of these samples results in separation of two main clusters,
where the left main-cluster contains one sub-cluster enriched for
low malignant potential (LMP), low grade and low stage samples
of ovarian origin (Figures 5A,B). The other samples in the left
main cluster as well as the second main-cluster contain mainly
malignant, high stage and high grade samples. Co-clustering of
Frontiers in Physiology | Systems Biology June 2013 | Volume 4 | Article 124 | 6
Kessler et al. Integrative analysis of cancer-related signaling pathways
FIGURE 4 | Continued
www.frontiersin.org June 2013 | Volume 4 | Article 124 | 7
Kessler et al. Integrative analysis of cancer-related signaling pathways
FIGURE 4 | Comparable network module activity differences in high
grade breast cancer samples of an independent data set. (A) Dendrogram
representation of a complete linkage hierarchical bi-clustering of network
module activity-based on expression data of 145 breast cancer samples of the
expO data set; the resulting dendrogram is annotated according to the clinical
sample annotation using the color code as indicated in the legend; labelings
are from top to down: labeling 4, tumor type; labeling 3, tumor grade; labeling
2, HER2 expression status; labeling 1, estrogen receptor (ER) expression
status. A cluster of mainly high grade ER and HER2-negative samples
analyzed further is indicated by a black vertical bar. (B) Magnification of
module activities that appear to distinguish the cluster of high grade ER and
HER2-negative samples from all other samples within the expO data set. (C)
Plot showing distribution of log10 values of all network module activity values
(blue bars) for all expO breast cancer samples versus log10 distribution of
gene-expression values (green bars) of all genes associated with the network.
(D) Network diagram of the top 15% differentially expressed modules
comparing the difference between average network module activity in high
grade versus all other samples; node color and node label size are initialized
with log2 difference of the average module and gene-expression values of
high grade versus all other samples; red color indicates expression above a
log2 difference ≥2.964 (max. 7.742). (E,F) Comparison of log2 differences in
(E) average PDGFR and (F) average INSR-pathway modules activity as
calculated for the Lu (blue bars) and expO (orange bars) data sets. The
thresholds for determination of the top 15% differentially activated modules
within both data sets are indicated by the horizontal bars. (G) Comparison of
log2 differences in average PDGFR module related gene-expression values as
calculated for the Lu and expO data sets. (H) Comparison of log2 differences
in average INSR module related gene-expression values as calculated for the
Lu and expO data sets. For comparison of differences of individual gene
expression with the differences in module activities, the thresholds for
determination of the top 15% differentially activated modules within both
data sets are indicated by the horizontal bars.
LMP samples into one distinct subcluster is as well achieved
using the network gene expression for clustering (Figure 5C).
To compare network module activity clustering with established
signature approaches, we performed clustering of samples using
two different ovarian cancer specific gene signatures (Denkert
et al., 2009; Mok et al., 2009), the general discriminatory signature
by Rhodes et al. (2004) and the breast cancer specific signa-
ture described by Paik et al. (2004). Using the Mok et al. (2009)
signature results in a sample distribution between the main clus-
ters that is very similar to network module activity and network
gene-expression values, including separation of all LMP samples
into one subcluster (Figure 5D). Clustering of the Denkert et al.
(2009), Rhodes et al. (2004), and Paik et al. (2004) gene signa-
tures results in less stringent separation of LMP samples from all
other samples (Figures 5E–G). Notably, the breast cancer specific
signature described by Paik et al. (2004) shows the least efficient
co-clustering with regard to the LMP samples comparing to all
other signatures (Figure 5G).
Several network modules appear to show differential activity
in the LMP- and co-clustering high grade samples versus all other
samples (Figure 6A). Again module activity in the network appears
to reflect the overall distribution of the expression of all network
associated genes (Figure 6B). To look into details of network mod-
ule activity differences between LMP and all other samples, we
again calculated the average expression levels for both groups
separately and then mapped the top 15% of differentially acti-
vated modules to the relevant signaling subnetwork (Figure 6C).
Interestingly, INSR-RTK, PDGFR-CoActivator, and PDGF-RTK
modules as well as the AP1 and MAPK-Inhibitor modules were
identified among the top differentially activated modules. Here,
INSR-RTK, AP1, and MAPK-Inhibitor module activities appears
to be higher, while PDGFR-RTK and PDGFR-CoActivator module
activities as well as PDGFR- and INSR-ADAPTOR modules appear
lower activated in LMP versus all other samples.
To test if similar differences in network module activity might
be identified in an independent data set, we performed analogous
analysis with samples provided by Anglesio et al. (2008) that also
include LMP samples. Using network module activity for hierar-
chical clustering results in two main clusters, one containing all
LMP samples while the other cluster contains only malignant and
all but one of the metastasis samples (Figure 7A). Again, activity
of several modules appears to distinguish the LMP cluster from
all other samples (Figure 7B) and, for example, the INSR-RTK,
PDGFR-CoActivator, and PDGF-RTK modules as well as the AP1,
MAPK-Inhibitor modules show differential activity between LMP
and all others samples, a finding that is highly similar to the situ-
ation found in the Tothill et al. (2008) data set. We again tested if
module activity in the network appears to reflect the overall distri-
bution of the expression of all network associated genes, and this
appears to be the case (Figure 7C). Mapping of the top 15% dif-
ferences of network module activity and average gene expression
between both sample groups to the relevant signaling subnetwork
results in a network activity pattern comparable between Tothill
and Anglesio data sets (Figure 7D). Indeed, direct comparison of,
e.g., AP1 and MAPK-Inhibitor differential module activity shows
that both modules are similarly differentially activated between
LMP and all other samples in both data sets (Figure 7E). We then
evaluated the contribution of differential gene expression to the
observed differences in AP1 and MAPK-Inhibitor module activity
and find that in the case of the AP1 module five of seven genes are
similarly differentially expressed between LMP and all other sam-
ples in both data sets, namely FOS, FOSB, FOSL2 as well as the JUN
and JUNB genes (Figure 7F). In case of the MAPK-Inhibitor the
differential expression of 5 of 20 genes appears to contribute most
to the observed differential module activity, namely the expression
of DUSP1, DUSP4, DUSP5, DUSP6, and RASA1, that are similarly
differentially expressed comparing LMP and all other samples in
both data sets (Figure 7G). Taken together, our results with breast
and ovarian cancer sample clustering suggest that our top down
network module activity-based approach is feasible for sample
stratification and initial follow up analysis for two different types
of cancers of different origins.
As hierarchical clustering provides a tool for visualization of
sample distribution between clusters but provides no quantitative
measure for clustering success we wanted to further substanti-
ate the assumption that our module-based network approach is
applicable for sample stratification using k-means clustering as
an independent, unsupervised method. We determined the opti-
mal number of expected clusters as two, using the clValid tool
for both the breast and ovarian cancer sample sets. As most sam-
ples in the data set are well annotated with respect to clinically
determined parameters, we analyzed those sample’s distribution
by the k-means algorithm regarding to known phenotypic repre-
sentations. We then calculated a p-value for each of the clustering
Frontiers in Physiology | Systems Biology June 2013 | Volume 4 | Article 124 | 8
Kessler et al. Integrative analysis of cancer-related signaling pathways
FIGURE 5 | Continued
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FIGURE 5 | Hierarchical clustering of an ovarian cancer sample data
set. (A) Heatmap representation of a complete linkage hierarchical
bi-clustering of network module activity, based on expression data of 278
ovarian cancer samples derived from the Tothill et al. (2008) data set; the
resulting sample distribution dendrogram is annotated according to the
clinical sample annotation using the color code as indicated in the legend;
labelings are from top to down: labeling 4, consolidated tumor grade;
labeling 3, stage code low (I and II) or high (III and IV); labeling 2, cancer
type LMP or malignant; labeling 1, primary tumor site ovary, fallopian tube,
or peritoneum. Regions analyzed in more detail in Figure 6A are indicated
by black vertical bars. (B) Magnification of the dendrogram from (A). (C)
Cluster dendrogram resulting from bi-clustering based on expression
values of all individual genes represented in the network. (D–G) Cluster
dendrograms resulting from bi-clustering of the samples based on
expression values of published discriminative gene signature sets
generated specifically for ovarian cancer samples (D) Mok et al. (2009), (E)
Denkert et al. (2009), as well as the signatures by (F) Rhodes et al. (2004),
and (G) Paik et al. (2004).
results using a chi-square test which can be used as a measure to
compare clustering success of different signatures to our network
module activity approach. For both the breast cancer Table 1 and
ovarian cancer Table 2 data sets we find that k-means clustering
using network activity results in separation of samples into the
expected number of clusters equally well as clustering using the
well established gene signatures for ovarian and breast cancer, as
judged by similarity of p-values achieved. Thus, k-means cluster-
ing provides further evidence that network module activity might
be a valid method for sample clustering, at least for some of the
selected parameters like ER grade in case of breast cancer and stage
code in case of the ovarian cancer samples. Our results suggest
that network module activity might indeed be a useful alternative
method for clustering of cancer samples of different origins and
performs well comparing to established discriminatory gene sets.
DISCUSSION
The approach to classify cancer samples according to their gene-
expression profile has become a standard method in recent years,
partially driven by the hope that discriminatory gene signatures
might guide treatment options for individual patients. Thus, the
search for best performing discriminatory gene-expression signa-
tures potentially covering more than one cancer type remains a
relevant topic in cancer research. Generally, all methods, includ-
ing ours, that rely on signaling pathway associated gene-expression
levels to compare biological samples share an assumption about
the most simple model hypothesis. This common model hypoth-
esis assumes that any differential effect on a pathways mRNA
expression level in a given sample is a linear functional response to
changes in signaling activity followed by differential transcription
of a specific subsets of mRNAs. However, this assumption might
be partially confounded by changes of mRNA levels due to other
effects, for example the differential activity of mRNA degradation
mechanisms between the samples. The overall mRNA degradation
rate in a cell depends on a complex interplay of multiple mech-
anisms relying on distinct protein–protein and protein-mRNA
interactions (Garneau et al., 2007). It is therefore possible that
differences in the expression or activity levels of any of these
mRNA degradation mechanisms in cancer cells obstruct the cor-
rect identification of pathway deregulation due to effects on mRNA
stability and overall mRNA abundance not appreciated by the ini-
tial hypothesis (López de Silanes et al., 2007). The identification of
pathway deregulation based on mRNA expression levels could also
be complicated by expression of cancer-related mRNAs containing
shorter 3′ untranslated regions that result in an increased mRNA
stability and more efficient translation into proteins (Mayr and
Bartel, 2009). While classical expression profiling studies of cancer
samples using chip hybridization might not address the expression
status of 3′ UTR variants, the application of advanced methods for
differential mRNA expression determination like RNA sequencing
should allow appreciation of any such 3′ related effects. Further-
more, the mechanisms affecting mRNA degradation as mentioned
above are either already known or highly likely to be regulated
posttranslationally in the context of the proliferating cancer cell;
for example protein phosphorylation downstream of ERK, JNK, or
p38 signaling is relevant for regulation of mRNA decay while the
molecular details of that regulation mechanism are not entirely
analyzed yet (López de Silanes et al., 2007). Non-RTK-coupled
signaling pathways have also been shown to affect mRNA decay
in cancer cells such as the regulation of mRNA degradation in
response to WNT signaling a mechanism that is under influence of
signaling crosstalk by the PI3K/AKT pathway (Gherzi et al., 2006;
Noubissi et al., 2006; Benjamin and Moroni, 2007). Thus, any
effect of an altered mRNA degradation machinery might affect
abundance of a specific subset of mRNAs under certain cellu-
lar conditions where distinct combinations of signaling pathways
are activated. Recent studies began to analyze in detail the rela-
tion between mRNA transcription and degradation in response to
extracellular stimuli but further work is clearly needed to extend
such studies to other than the analyzed cell types and signaling
events (Cheadle et al., 2005; Hao and Baltimore, 2009; Rabani et al.,
2011; Pai et al., 2012). With respect to the genes associated with
the signaling network presented in this study we find that some
network genes are indeed known to be regulated on the level of
mRNA degradation, such as the VEGF and FGF8 mRNAs (Alonso,
2012). Furthermore, preliminary bioinformatic analysis suggests
that the mRNA of 17 of our network genes might contain AU-rich
elements in the untranslated region (data not shown). Of these
genes only DUSP1 has been identified as a relevant differentially
activated gene in this study. The predicted ARE motif within the 17
genes might therefore allow regulation of mRNA stability by RNA
binding proteins and degradation related effects might affect the
activity of the network modules that these genes are attributed to.
However, given the incomplete knowledge about altered mRNA
degradation mechanisms in the analyzed samples we decided to
retain the most simple model assumption for our study, namely
that mRNA levels directly reflect the activity of the signaling net-
work. A systematic analysis of the response of mRNA transcription
and degradation over time in response to distinct signaling events
and combinations thereof would clearly be highly informative to
better understand the dynamic details of the systems biology of
decay pathways in cancer samples.
In this work, we explore the idea of a top down approach for
sample stratification based on a module-based network of cancer
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FIGURE 6 | Pathway activity analysis of the LMP ovarian cancer
subcluster. (A) Regions of the heatmap in Figure 5 that appear to distinguish
low malignancy potential (LMP) samples from all other ovarian cancer
samples. (B) Plot showing distribution of log10 values of all network module
activity values (blue bars) for all Tothill et al. (2008) ovarian cancer samples
versus log10 distribution of gene-expression values (green bars) of all genes
associated with the network. (C) Network diagram of the top 15% differential
expressed modules and genes comparing the difference between average
network module activity in LMP versus all other samples; node color and
node label size are initialized with log2 difference of the average
gene-expression values of LMP versus all other samples; red color indicates
expression above a log2 difference ≥6.605 (max. 9.768).
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FIGURE 7 | Continued
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FIGURE 7 | Comparable network module activity differences between
LMP and all other ovarian cancer samples of an independent data set. (A)
Dendrogram representation of a complete linkage hierarchical bi-clustering of
network module activity, based on expression data of 83 ovarian cancer
samples of the Anglesio et al. (2008) data set; the resulting dendrogram is
annotated according to the clinical sample annotation using the color code as
indicated in the legend; labelings are from top to down: labeling 4,
consolidated tumor grade; labeling 3, stage code low (I and II) or high (III and
IV); labeling 2, cancer type LMP or malignant; labeling 1, primary tumor site
ovary or metastasis. (B) Depiction of network module activities that appear to
distinguish the cluster of LMP samples from all other samples within the
Anglesio et al. (2008) data set. (C) Plot showing distribution of log10 values of
all network module activity values (blue bars) for all Anglesio et al., ovarian
cancer samples versus log10 distribution of gene-expression values (green
bars) of all genes associated with the network. (D) Network diagram of the
top 15% differentially expressed modules comparing the difference between
average network module activity in LMP versus all other samples; node color
and node label size are initialized with log2 difference of the average module
activity and gene-expression values of LMP versus all other samples; dark red
color indicates expression above a log2 difference ≥3.455 (max. 9.631). (E)
Comparison of log2 differences in average AP1 and MAPK-Inhibitor module
activity as calculated for the Tothill (blue bars) and Anglesio (orange bars) data
sets. (F) Comparison of log2 differences in average AP1 module associated
gene-expression values as calculated for the Anglesio et al. (2008) and Tothill
et al. (2008) data sets. (G) Comparison of log2 differences in average
MAPK-Inhibitor module associated gene-expression values as calculated for
the Anglesio et al. and Tothill et al. data sets. For comparison of differences of
individual gene expression with the differences in module activities, the
thresholds for determination of the top 15% differentially activated modules
within both data sets are indicated by the horizontal bars.
relevant signaling pathways and the approach using the network
module activity as a proxy for pathway activity is consistent with
previous work (Chuang et al., 2007). For quantitative comparison
of our network module-based approach with published gene sig-
natures we chose the widely used k-means clustering algorithm
as one of the most simple and effective approaches to sample
clustering (Gibbons and Roth, 2002). Using the k-means algo-
rithm we tested the non-linear Spearman correlation (data not
shown) and the linear Pearson correlation measures for sample
clustering. The Pearson correlation measure lead to a significant
sample clustering in case of ER-grade for breast cancer and tumor
stage for ovarian cancer, respectively. Currently, we cannot exclude
that alternative unsupervised clustering algorithms or correlation
measures might lead to more significant findings for additional
clinical parameters in the analyzed data sets and further work
is needed to test this hypothesis. Furthermore, for assembly of
our network, we considered several of the most established cancer
pathways, while leaving out other signaling pathways even if they
might be of relevance for a distinct group of cancer types or their
general contribution to cancer development has yet to be estab-
lished more firmly. Also, our network, in its current state, does
not consider other cellular processes coupled to signaling events
such as the DNA damage response or the core cell cycle regulating
machinery which are known to be frequently deregulated in cancer
(Bartek et al., 2007; Harper and Elledge, 2007; Williams and Stoe-
ber, 2007; Basu et al., 2012). Albeit those limitations, our results
suggest that the established module-based core signaling network
can be useful to discriminate relevant subclusters of samples from
two different cancer types. In particular, visualizing the network
module activity in a heatmap-like representation of hierarchical
clustering allows an immediate impression of the levels at which
transcriptional deregulation takes place in the network hierarchy
and might guide toward potentially interesting sub-modules for
follow up analysis as we have shown for several examples in the
breast and ovarian cancer data sets. In the case of the ovarian can-
cer samples, the identification of a potentially higher activity of
the MAPK-Inhibitory module in LMP samples is consistent with
previous findings. Indeed, the work of Anglesio et al. (2008) that
generated one of the data sets we used for our analysis identified
the expression of DUSP family members 1/4/5/6 as discriminatory
for the LMP subcluster. However, the relevance of the other iden-
tified modules for the LMP sub-cluster phenotype is less clear. For
example, relevance of elevated AP1 module activity for establish-
ment or maintenance of the LMP phenotype remains to be shown
by independent experiments, for example using RNAi mediated
mRNA knockdown in LMP derived cell lines tested for their malig-
nant and/or invasive potential in vitro. For a subset of breast cancer
samples our approach indicates a potentially common relatively
low activity of PDGFR- and INSR-pathways occurring at different
levels within the network hierarchy. This observation in two inde-
pendent data sets is consistent with the notion that a high grade
ER- and HER2-negative sub-cluster might comprise primarily of
samples with low aggressiveness as previous reports show that
PDGFR expression is rather associated with high histopatholog-
ical grade in ER-negative, HER2-positive breast cancer samples
(Carvalho et al., 2005; Paulsson et al., 2009; Ahmad et al., 2011)
and that INSR up-regulation is imminent in approximately 90%
of breast cancer samples with bad prognosis (Nielsen et al., 2004;
Law et al., 2008).
Interestingly, we find that network module activity-based clus-
tering performs well in cancer types of two different origins
comparing to established cancer specific gene signatures that have
been generated specifically for each of the tumor types separately.
This might be intriguing as the overlap between the genes in our
network and the established discriminatory gene sets is minimal.
Indeed, we identify a minimal overlap of four different network
genes with the breast cancer signatures of Wang et al. (2005)
(HDAC1, PIAS3) and van’t Veer et al. (2002) (DUSP4, DVL3)
and a maximal overlap of 11 network genes with the ovarian can-
cer specific gene signature of Mok et al. (2009) (MAPK9, ARAF,
PEPB1, MAPK1, TGFB3, ERBB2, ADAM12, GREM1, SMAD2,
JAG2, GLI3). However, success of our network approach for sam-
ple clustering might be partially explained by the observation that
several gene sets can be derived from the same set of cancer samples
that perform equally well for sample stratification by clustering
(Ein-Dor et al., 2005; Fan et al., 2006; Abba et al., 2010). Thus, given
that the experimental outline, the underlying statistical method
for gene set definition and other factors have great influence on
gene signature determination it might be less surprising that our
network-based gene set provides another effective means for sam-
ple discrimination. However, we believe that the discrimination of
different sub-modules guided by the functional relevance of the
associated genes provides a benefit over other methods using more
general pathway annotations and allow assessment of pathway
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Table 1 | k -Means clustering of breast cancer samples.
Lu et al. dataset expO dataset
Network activity values cluster 1 cluster 2 p-value Network activity values cluster 1 cluster 2 p-value
ER:neg 19 33 6.14E-04 ER:neg 29 24 5.31E-01
ER:pos 43 18 ER:pos 44 48
HER2:neg 46 39 9.52E-01 HER2:neg 53 54 8.89E-01
HER2:pos 16 12 HER2:pos 20 18
B-R grade:low 28 18 3.84E-01 B-R grade:low 30 35 4.58E-01
B-R grade:high 34 33 B-R grade:high 43 37
Oncotype signature cluster 1 cluster 2 p-value Oncotype signature cluster 1 cluster 2 p-value
ER:neg 17 35 2.66E-04 ER:neg 29 24 9.97E-01
ER:pos 42 19 ER:pos 49 43
HER2:neg 45 40 9.58E-01 HER2:neg 55 52 4.36E-01
HER2:pos 14 14 HER2:pos 23 15
B-R grade:low 28 18 1.82E-01 B-R grade:low 33 32 6.24E-01
B-R grade:high 31 36 B-R grade:high 45 35
Rhodes et al. signature cluster 1 cluster 2 p-value Rhodes et al. signature cluster 1 cluster 2 p-value
ER:neg 18 34 2.90E-04 ER:neg 24 29 8.69E-01
ER:pos 43 18 ER:pos 39 53
HER2:neg 45 40 8.66E-01 HER2:neg 43 64 2.55E-01
HER2:pos 16 12 HER2:pos 20 18
B-R grade:low 25 21 8.99E-01 B-R grade:low 20 45 9.11E-03
B-R grade:high 36 31 B-R grade:high 43 37
Network genes cluster 1 cluster 2 p-value Network genes cluster 1 cluster 2 p-value
ER:neg 37 15 1.06E-04 ER:neg 23 30 3.98E-01
ER:pos 20 41 ER:pos 48 44
HER2:neg 43 42 8.70E-01 HER2:neg 53 54 9.68E-01
HER2:pos 14 14 HER2:pos 18 20
B-R grade:low 21 25 5.14E-01 B-R grade:low 35 30 3.72E-01
B-R grade:high 36 31 B-R grade:high 36 44
van’t Veer et al. signature cluster 1 cluster 2 p-value van’t Veer et al. signature cluster 1 cluster 2 p-value
ER:neg 36 16 2.40E-04 ER:neg 23 30 9.43E-01
ER:pos 20 41 ER:pos 38 54
HER2:neg 43 42 8.70E-01 HER2:neg 46 61 8.52E-01
HER2:pos 13 15 HER2:pos 15 23
B-R grade:low 22 24 9.10E-01 B-R grade:low 31 34 2.86E-01
B-R grade:high 34 33 B-R grade:high 30 50
Wang et al. signature cluster 1 cluster 2 p-value Wang et al. signature cluster 1 cluster 2 p-value
ER:neg 37 15 2.38E-05 ER:neg 24 29 7.08E-01
ER:pos 18 43 ER:pos 46 46
HER2:neg 41 44 9.55E-01 HER2:neg 53 54 7.50E-01
HER2:pos 14 14 HER2:pos 17 21
B-R grade:low 19 27 2.68E-01 B-R grade:low 41 24 2.30E-03
B-R grade:high 36 31 B-R grade:high 29 51
Results of k-means-based clustering of the network module activity or expression values for all network genes from the Lu et al. (2008) and expO data sets in
comparison to the clustering results based on the expression value of genes overlapping the signature gene sets ofWang et al. (2005), van’t Veer et al. (2002), Paik
et al. (2004) or Rhodes et al. (2004).
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Table 2 | k -Means clustering of ovarian cancer samples.
Tothill et al. dataset Anglesio et al. dataset
Network activity values cluster 1 cluster 2 p-value Network activity values cluster 1 cluster 2 p-value
Type:malignant 117 144 1.80E-01 Type:malignant 28 30 2.81E-01
Type:LMP 11 6 Type:LMP 16 9
Stage code:high 100 137 3.43E-03 Stage code:high 34 30 8.23E-01
Stage code:low 28 13 Stage code:low 10 9
Grade:high 118 141 7.20E-01 Grade:high 29 29 5.50E-01
Grade:low 10 9 Grade:low 15 10
Denkert et al. signature cluster 1 cluster 2 p-value Denkert et al. signature cluster 1 cluster 2 p-value
Type:malignant 125 136 5.33E-01 Type:malignant 33 25 2.40E-01
Type:LMP 10 7 Type:LMP 10 15
Stage code:high 106 131 3.65E-03 Stage code:high 35 29 4.82E-01
Stage code:low 29 12 Stage code:low 8 11
Grade:high 127 132 7.30E-01 Grade:high 33 25 2.40E-01
Grade:low 8 11 Grade:low 10 15
Mok et al. signature cluster 1 cluster 2 p-value Mok et al. signature cluster 1 cluster 2 p-value
Type:malignant 107 154 8.10E-01 Type:malignant 34 24 7.51E-01
Type:LMP 7 10 Type:LMP 13 12
Stage code:high 100 137 4.26E-01 Stage code:high 35 29 6.96E-01
Stage code:low 14 27 Stage code:low 12 7
Grade:high 106 153 8.88E-01 Grade:high 34 24 7.51E-01
Grade:low 8 11 Grade:low 13 12
Oncotype signature cluster 1 cluster 2 p-value Oncotype signature cluster 1 cluster 2 p-value
Type:malignant 122 139 8.45E-01 Type:malignant 25 33 8.68E-01
Type:LMP 7 10 Type:LMP 11 14
Stage code:high 113 124 3.92E-01 Stage code:high 29 35 6.96E-01
Stage code:low 16 25 Stage code:low 7 12
Grade:high 120 139 8.80E-01 Grade:high 27 31 5.17E-01
Grade:low 9 10 Grade:low 9 16
Rhodes et al. signature cluster 1 cluster 2 p-value Rhodes et al. signature cluster 1 cluster 2 p-value
Type:malignant 125 136 4.20E-02 Type:malignant 28 30 6.84E-01
Type:LMP 13 4 Type:LMP 14 11
Stage code:high 109 128 5.85E-03 Stage code:high 31 33 6.44E-01
Stage code:low 29 12 Stage code:low 11 8
Grade:high 128 131 9.74E-01 Grade:high 27 31 3.76E-01
Grade:low 10 9 Grade:low 15 10
Network genes cluster 1 cluster 2 p-value Network genes cluster 1 cluster 2 p-value
Type:malignant 134 127 4.13E-01 Type:malignant 32 26 4.87E-01
Type:LMP 11 6 Type:LMP 11 14
Stage code:high 116 121 1.60E-02 Stage code:high 35 29 4.82E-01
Stage code:low 29 12 Stage code:low 8 11
Grade:high 134 125 7.79E-01 Grade:high 31 27 8.29E-01
Grade:low 11 8 Grade:low 12 13
Results of k-means-based clustering of the network module activity or expression values for all network genes from theTothill et al. (2008) and Anglesio et al. (2008)
data sets in comparison to the clustering results based on the expression value of genes overlapping the signature gene sets of Mok et al. (2009), Denkert et al.
(2009), Rhodes et al. (2004), and Paik et al. (2004).
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related gene-expression independent of prior knowledge of cancer
specific effects.
It should be emphasized that the success of statistical methods
to derive gene signatures for a specific cancer subtype can par-
tially be confounded by the intrinsic heterogeneous nature of the
analyzed cancer sample, e.g., with respect to altered mRNA decay
related mechanisms as described above. Also, cancer samples of
different origin can differ widely with respect to the mutational
status of oncogenes and tumor suppressor genes and/or gene and
chromosome copy number alterations, respectively. Even subtypes
of one cancer type can be discriminated by mutational status
as exemplified for the group of so called triple negative breast
cancer. While this cancer subtype is characterized by absence
of estrogen and progesterone receptors as well as HER2 over-
expression, triple negative breast cancer samples appear to con-
stitute a heterogeneous group as mutations in TP53, PIK3CA, and
PTEN have recently been shown to confer cancer driving proper-
ties in most but not all cases (Curtis et al., 2012; Shah et al., 2012).
Acknowledging the mutational status within a given cancer sample
might therefore dramatically improve the value of any predictive
method including our network module-based approach. Devel-
opment of such a detailed signaling network of cancer relevant
pathways in the future is therefore of great scientific and clinical
interest.
MATERIALS AND METHODS
ESTABLISHMENT OF CANCER RELEVANT SIGNALING MODULE-BASED
NETWORK
We generated a comprehensive list of human cancer-related sig-
naling components based upon pathway information obtained
from REACTOME database version 40 (Croft et al., 2011), com-
plemented with interaction data for individual signaling adap-
tors, receptors/ligands, and peripheral modifiers derived from a
PUBMED gene entry search. Genes encoding for ligands, recep-
tors or RTKs as well as adaptor proteins of the same signaling
pathway were then grouped into distinct modules that con-
tribute to a common upstream module. The upstream modules
were linked to pathway specific downstream modules includ-
ing MAPK-, PI3K/AKT-, PLCG-, Rho/Jnk-, SRC-, JAK/STAT-,
p38-, NFkB-SignalingComplex-, and SMAD-modules. Those
downstream modules are connected via a pathway’s “effectors”
entities (activeERK, activeAKT, etc.) to downstream transcription
factor modules including MYC, AP1, GLI, and NICD transcrip-
tion factors. To compare the composition of ERBB and MAPK
pathway modules described in our network to previous pathway
annotations we consulted the KEGG (Ogata et al., 1999), BioCarta
(http://www.biocarta.com),and MSigDB databases (Subramanian
et al., 2005). To identify AU-rich elements in the UTR of signal-
ing network associated genes we used the online tool ARED 3.0
(Bakheet et al., 2006).
ASSESSMENT OF NETWORK MODULE ACTIVITY
For initialization of our network model with expression data
we used raw data of two comprehensive gene-expression pro-
filing studies each for breast and ovarian cancer that used the
Affymetrix U133A or U133 plus 2.0 platforms for data generation
(breast cancer GSE5460 and GSE2109, Ovarian cancer GSE9891
and GSE12172). We normalized the individual raw data using the
quantile normalization method. We selected only those samples
for analysis that are annotated with respect to all individual clini-
cal markers. We then extracted the normalized expression values of
all genes contributing to the network modules from those data for
further analysis. We assume that a similar cellular phenotype and
clinical representation of the analyzed samples might arise not only
from deregulation of the exact same gene within a module at the
same hierarchical step within the network but also from: (i) dereg-
ulation of normally co-expressed and functionally interchangeable
proteins within the same network module and/or (ii) deregula-
tion of the same pathway on different levels within the network
hierarchy potentially involving CoActivators/CoInhibitor regula-
tory modules. After determining gene-expression values for all the
genes of all modules a “network module activity” was calculated
for each module as the median value of all the gene-expression
values of the given module. We then tested the feasibility of using
these network module activity values to distinguish cancer sub-
types within the two distinct breast and ovarian cancer patient
cohorts in comparison to all genes in the network (network genes)
and previously published discriminatory gene sets as described in
detail in the main text.
To determine differential module activation between selected
sample subclusters we calculated the average of the network mod-
ule activity for the subcluster of interest and all other samples
individually and then computed the differences in average mod-
ule activity between these sub-groups. To compare the differential
activation of network module activity between two data sets we
calculated the difference of average network module activity of
clusters of interest in each of the data sets individually and then
calculated the absolute values of the differences. We then deter-
mined the top 15% of differences for each data set individually and
selected for further analysis those pathways modules that showed
the same trend for higher or lower network module activity within
both data sets.
SAMPLE CLUSTERING
We subjected the standardized median network module activ-
ity values for complete linkage hierarchical clustering of the
patient samples using Pearson correlation as the distance measure.
The heatmap-like representation in the hierarchical clustering is
achieved through standardization of the data over all samples
resulting in a mean gene vector of zero and a standard deviation
of one; red and green labels were assigned to values with a higher
and lower expression than the mean, respectively. Furthermore,
we applied k-means clustering as an unsupervised classification
method on all patient samples. We tested Spearman and Pearson
correlation measures for k-means clustering and found that with
regard to the ER-status, the Pearson correlation resulted in sample
clustering with more significant p-values. Therefore, we decided
to keep Pearson correlation rather than Spearman correlation for
further analysis. In addition to the network module activity value,
we used the normalized expression values of all network genes
or those genes representing known discriminative gene signatures
for hierarchical and k-means-based clustering. We determined the
optimal number of expected clusters independently of the data
labels given by the data sets and found that a cluster number of
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two is optimal for all four data sets (data not shown). For this clus-
ter stability analysis we used the clValid tool (Brock et al., 2011)
and determined the expected number of clusters according to the
Silhouette width measure. In order to assess the quality of result-
ing k-means clusterings we assigned each clustering the p-value
from a chi-square test using the respective known annotations. It
is therefore possible to compare the quality of the clustering results.
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